Virtu KCG Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Virtu KCG Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-18,300	Closed	-$1.2M	–	3622
2015 Q4	$1.2M	Sell	18,300 -16,800	-48%	-$1.04M	0.02%	708
2015 Q3	$1.98M	Buy	35,100 +8,700	+33%	+$564K	0.03%	457
2015 Q2	$1.56M	Buy	+26,400	New	+$1.63M	0.03%	559
2015 Q1	–	Sell	-21,600	Closed	-$1.24M	–	3859
2014 Q4	$1.24M	Buy	21,600 +8,000	+59%	+$446K	0.02%	748
2014 Q3	$731K	Sell	13,600 -14,700	-52%	-$779K	0.01%	1289
2014 Q2	$1.48M	Sell	28,300 -54,600	-66%	-$2.79M	0.02%	784
2014 Q1	$4.38M	Buy	82,900 +56,000	+208%	+$2.59M	0.05%	305
2013 Q4	$1.08M	Buy	+26,900	New	+$1.06M	0.01%	1152

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtu KCG Holdings's TEVA Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 55,676 shares — an estimated $1.79M sold.

Virtu KCG Holdings first reported a position in TEVA in Q3 2013 and held it in 14 quarters. The position peaked at $8.16M in Q3 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Virtu KCG Holdings reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 55,676 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.79M.
Virtu KCG Holdings first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 14 quarters.
Virtu KCG Holdings's Teva Pharmaceuticals position peaked at $8.16M in Q3 2016.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.